NDA 021560 · Novartis
Zortress
Everolimus · Oral · Kinase Inhibitor; mTOR Inhibitor Immunosuppressant
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Apr 20, 2010
Approved uses
3
Original approval plus efficacy supplements
Registered trials
881
126 Phase 3, 57 recruiting
FAERS reports
18,496
16,082 serious, 2,839 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MALIGNANCIES, SERIOUS INFECTIONS, KIDNEY GRAFT THROMBOSIS, NEPHROTOXICITY and MORTALITY IN HEART TRANSPLANTATION Malignancies and Serious Infections Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe Zortress. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.1)]. Increased susceptibility to infection and the possible development of malignancies, such as lymphoma and skin cancer, may result from immunosuppression [see Warnings and Precautions (5.2, 5.3)]. Kidney Graft Thrombosis An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was...
What it is approved for
From the label in effect Sep 16, 2026.
Zortress is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving a: Kidney Transplant : At low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids ( 1.1) Liver Transplant : Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids ( 1.2 , 5.5 ) Limitations of Use : Safety and efficacy have not been established in the following: Kidney transplant patients at high immunologic risk ( 1.3 ) Recipients of transplanted organs other than kidney or liver ( 1.3 , 5.7 ) Pediatric patients (less than 18 years) ( 1.3 ) 1.1 Prophylaxis of Organ Rejection in Kidney Transplantation Zortress is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunologic risk receiving a kidney transplant. Zortress is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. Therapeutic drug monitoring (TDM) of everolimus and cyclosporine is recommended for all patients receiving these products. 1.2 Prophylaxis of Organ Rejection in Liver Transplantation Zortress is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. Zortress is to be administered no earlier than 30 days posttransplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids. TDM of everolimus and tacrolimus is recommended for all patients receiving these products. 1.3 Limitations of Use The safety and efficacy of Zortress has not been established in the following populations: Kidney transplant patients at high immunologic risk. Recipients of transplanted...
Mechanism: Everolimus inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes. In cells, everolimus binds to a cytoplasmic protein, the FK506 Binding Protein-12 (FKBP-12), to form an immunosuppressive complex (everolimus: FKBP-12) that binds to and inhibits the mammalian target of rapamycin (mTOR), a key regulatory kinase. In the presence of everolimus phosphorylation of p70 S6 ribosomal protein kinase (p70S6K), a substrate of mTOR, is inhibited. Consequently, phosphorylation of the ribosomal S6 protein and subsequent protein synthesis and cell...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 12, 2016 Supplement 19 · Efficacy LetterLabel
- Feb 15, 2013 Supplement 6 · Efficacy LetterLabel
- Apr 20, 2010 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewSummary Review
4 products under this application
- ZORTRESS · EVEROLIMUS 1MG · TABLET, ORAL · Prescription · TE AB
- ZORTRESS · EVEROLIMUS 0.5MG · TABLET, ORAL · Prescription · TE AB
- ZORTRESS · EVEROLIMUS 0.75MG · TABLET, ORAL · Prescription · TE AB
- ZORTRESS · EVEROLIMUS 0.25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Everolimus" as an intervention, any sponsor and status, largest first.
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- Colchicine and Spironolactone in Patients with MI / SYNERGY Stent RegistryPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03048825 · 7,264 participants · Start Feb 1, 2018 · Primary completion Aug 9, 2024
Drug: Colchicine; Spironolactone and 2 more · For: ST Elevation Myocardial Infarction; Non ST Elevation Myocardial Infarction
Sites: Bakersfield, California; Washington D.C., District of Columbia; Chicago, Illinois · 109 sites in all
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 StudyPivotal-lookingStatus unknown
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT04609111 · 6,002 participants · Start Jan 29, 2021 · Primary completion Dec 31, 2023
Drug: No aspirin; 1-month DAPT · For: Acute Coronary Syndrome
Sites: Kyoto, Japan
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimenPivotal-lookingStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT01267734 · 3,750 participants (planned) · Start Jun 2010 · Primary completion Dec 2011
Drug: Triple anti-platelet therapy (TAT); Double-dose clopidogrel anti-platelet therapy (DDAT) · For: Coronary Heart Disease
Sites: Seoul, South Korea
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)Pivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02193971 · 3,429 participants · Start Jul 2014 · Primary completion Oct 2020
Drug: Prasugrel 5mg · For: Acute Coronary Syndrome
Sites: Seoul, South Korea
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACSPivotal-lookingStatus unknown
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT03462498 · 3,008 participants · Start Apr 2, 2018 · Primary completion Dec 31, 2021
Drug: 1-months DAPT; 12-month DAPT · For: Acute Coronary Syndrome; Acute Myocardial Infarction; Coronary Artery Disease and 2 more
Sites: Kyoto, Japan
Boston Scientific CorporationIndustry
NCT01589978 · 2,681 participants · Start May 2012 · Primary completion Aug 2014
Drug: Aspirin; P2Y12 antagonist · For: Coronary Artery Disease
Sites: Huntsville, Alabama; Mobile, Alabama; Jonesboro, Arkansas · 52 sites in all
- Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerPivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT00567554 · 2,600 participants · Start Oct 2007 · Primary completion Aug 2011
Drug: epirubicin - cyclophosphamide / docetaxel; epirubicin - cyclophosphamide / docetaxel + bevacizumab and 4 more · For: Breast Cancer
Sites: Frankfurt am Main, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression1,602
- off label use1,422
- diarrhoea1,307
- drug ineffective1,035
- death916
- fatigue898
- nausea816
- product use in unapproved indication764
- disease progression762
- dyspnoea704
- pyrexia682
- pneumonia667
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 5 |
| 2007 | 15 |
| 2008 | 33 |
| 2009 | 88 |
| 2010 | 120 |
| 2011 | 362 |
| 2012 | 457 |
| 2013 | 428 |
| 2014 | 501 |
| 2015 | 744 |
| 2016 | 722 |
| 2017 | 825 |
| 2018 | 1,244 |
| 2019 | 1,401 |
| 2020 | 1,934 |
| 2021 | 1,624 |
| 2022 | 1,780 |
| 2023 | 1,834 |
| 2024 | 1,800 |
| 2025 | 1,391 |
| 2026 | 1,186 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zortress (Everolimus)
2024 spending
$1.4M
Beneficiaries
75
382 claims
Per beneficiary
$18,220
$22.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,912,118 |
| 2021 | $9,443,154 |
| 2022 | $4,223,817 |
| 2023 | $1,994,088 |
| 2024 | $1,366,474 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Multicenter Study
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC, Shah MH, Ito T, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Multicenter Study
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J, Campone M, Piccart M, et al. · N Engl J Med 2012 · Clinical Trial, Phase III, Comparative Study
- Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, et al. · J Am Soc Nephrol 2018 · Equivalence Trial, Multicenter Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.